arrow
K

Kenneth H. Yu

Memorial Sloan Kettering Cancer Center
H指数:46
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Sensitivity of metastatic mucinous tailgut cyst adenocarcinoma to gemcitabine and radiation: a case report

对转移性黏液性尾部肠囊肿腺癌对吉西他滨和放射治疗的敏感性:一篇病例报告

2025-12-190
OAAI
Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma

Keane, F.; Saadat, L.V.; O’Connor, C.A.; Chou, J.F.; Bowman, A.S.; Xu, F.; Crowley, F.; Debnath, N.; Schoenfeld, J.D.; Singhal, A.; 等. 循环肿瘤DNA在胰腺导管腺癌中的临床应用价值及组织一致性. J. Natl. Cancer Inst. 2025, 117, djaf139. [Google Scholar] [CrossRef]

2025-08-011
PRE
Nonoperative Management of Technically Resectable Pancreatic Cancer With Ablative Radiation Therapy

技术上可切除的胰腺癌采用消融放射治疗的非手术治疗管理

2025-04-101
PRE
Phase II trial of Pembrolizumab and OLApaRib (POLAR) maintenance for select patients (pts) with metastatic pancreatic cancer (mPC) with (A) homologous recombination deficiency (HRD), (B) non-core HRD (ncHRD) and (C) exceptional response to platinum

II期临床试验,评估Pembrolizumab和OLApaRib(POLAR)用于具有同源重组缺陷(HRD)、非核心同源重组缺陷(ncHRD)以及对铂类药物有例外反应的转移性胰腺癌(mPC)患者的维持治疗。

2024-09-010
PRE
Salvage Ablative Radiotherapy for Isolated Local Recurrence of Pancreatic Adenocarcinoma following Definitive Surgery
2024-04-301
OAAI
Clinico-genomic characterization of N=2,460 pancreatic adenocarcinoma identifies KRASMUT dosage as prognostic of overall survival across disease stages
2024-01-160
PRE
Dual primary pancreas cancers - Related or independent lesions?
2024-01-160
PRE
Deep genomic and single cell molecular profiles define immunogenic pancreatic cancer
2024-01-160
PRE
Molecular profiles and single cell analysis identify immunogenic pancreatic ductal adenocarcinoma (iPDAC)
2023-04-040
PRE
Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer
2021-11-2515
OAAI